US Senate Finance Drug Pricing Bill Would Have ‘Negligible’ Impact, Analyst Predicts

Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests.